J - - 13 - - 0 6

| APS | Roo'd Form 0 9 7 CB 2000 | C |
| Docket No.: 05432/100M680-US1 | (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Thomas Pittelkow et al.

Application No.: 10/550,419 Confirmation No.: 3350

Filed: September 20, 2005 Art Unit: Not Yet Assigned

For: INTERMEDIATES FOR THE PREPARATION Examiner: Not Yet Assigned

OF CITALOPRAM AND ESCITALOPRAM

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- 1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)
 - []A. Within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
 - [X] B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
 - [] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.
 - (check one of the boxes "i" and "ii" below:)
 - [] i. Counsel states that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or (b) was not cited in a communication

from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[] ii. A check for the fee set forth in 1.17(p), presently believed to be \$180, is

2

- [] D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant petitions under 37 C.F.R. 1.97(d) for the consideration of this IDS. Under 37 C.F.R. 1.17(i) a check in the amount of \$130.00 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS; or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- 2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO/SB/08) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A, B and/or C and fill in blanks, if appropriate.)

- [X] A. Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the published United States Patent Application(s) and/or United States Patent(s) listed on PTO/SB08 is/are not being submitted.
- []B. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- [] C. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:

[SERIAL NO. & FILING DATE].

Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449 and/or PTO/SB/08 from the files of the prior application(s) or a fresh PTO/SB/08 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.

Application No.: 10/550,419

[X] 3. Cite Nos.	7, 12,	and	18	are	not i	n the	English	language.	In	accordance	with
1 98(c) Applicant states:											

3

- [X] An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.
- [] The requirement for a concise explanation of the relevance of any foreign language document is satisfied by the attached search report; citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP \$609).
- [X] A concise explanation of the relevance of document(s) 18 is set forth as follows: See molecular structures shown in document.
- [] A concise explanation of the relevance of document(s) ____ can be found on page(s) of the specification.
- [] A concise explanation of document(s) ____ can be found on the attached sheet.
- [X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 in the preamble to the final rules; 1135 OG 13 at 20).

[X] 5. Other information being provided for the examiner's consideration follows:

An International Search Report, dated July 19, 2004, which issued during the prosecution of International Application No. PCT/DK2004/000177, which corresponds to the present application.

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Application No.: 10/550,419

Early and favorable consideration is earnestly solicited.

Dated: February 9, 2006

Respectfully submitted,

Dianna Goldenson

Registration No.: 52,949 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700 (212) 527-7701 (Fax)

Attorneys/Agents For Applicant

FEB 0 9 2000 E

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control numb Complete if Known Substitute for form 1449A/B/PTO Application Number 10/550,419 - Conf.# 3350 INFORMATION DISCLOSURE Filing Date September 20, 2005 STATEMENT BY APPLICANT First Named Inventor Thomas Pittelkow Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Sheet 1 of 2 Attorney Docket Number 05432/100M680-US1

Г	U.S. PATENT DOCUMENTS							
E.	Examiner C	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
	tials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
	//	1.C.	4,650,884	03-17-1987	Bogeso			
		2	4,943,590	07-24-1990	Boegesoe et al.			
П		3	6,403,813		Petersen et al.			
I	,	4	6,458,973	10-01-2002	Dall'Asta et al.			
V	_/N	(5/	3,607,884	09-21-1971	Forney			
L								
⊢								

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰	
1 /N	.6./	WO 00/39112	07-06-2000	H. Lundbeck			
	7	JP 62185070 A2	08-13-1987	Sankyo Co.			
	8	WO 00/44738	08-03-2000	Lundbeck			
	9	WO 98/19513	05-14-1998	H. Lundbeck		П	
	10	WO 98/19511	05-14-1998	H. Lundbeck			
	11	WO 99/16743	04-08-1999	Whang et al.			
	12	DE 2630927	01-19-1978	BASF		Г	
Π.	13	GB 1578989	11-12-1980	BASF			
\mathbf{W}^{-}	14	EP 1118614	07-25-2001	Norpharma		Г	
/N	<u>(†5</u>	WO 01/32642	05-10-2001	Lundbeck		F	

"EXAMINER: Initial if reference considered, whether or not clasion is in conformance with MPEP 609. Draw line through clasion if not in conformance and not considered, include copy of this form with next communication to applicant. "Pursuant to the Notice issued by the United States Patient and Travemant Office and add 17,12 (2004) which give requirements of 37 CFR 9,1 Stag(3/1)), a copy of the United States Patient on PTO/SSIO 31 on its uplimited. "Applicants unique clasion displation number (optional)." See Kinde Codes of USPTO Patient Documents at www. upbb age or MPEP 901.04. "Enter Office that issued the code of the Codes of USPTO Patient Documents, the indication of the year of the right of the Emperor must proceed the code of the Codes of the Codes of the Special Codes of the Code

		NON PATENT LITERATURE DOCUMENT	rs		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
. /N.	C16	Hyttel, Prog. Neuro-Psychopharmacol & Biol Psychiat, 1982, (6):277-295		
	17	Gravem, Acta Psychiatr Scand, 1987, (75):478-486			
18 Tirouflet, Bull Soc Sci Bretagne, 1951, (26):35-43					
V.	19	Levy and Stephen, J Chem Soc, 1931, 867-870			
N/N	(20)	Forney, J Org Chem, 1970, (35):1695-1696			
Examiner Signature		Nizal Chandrakumar/ Dat Cor	te nsidered	05/15/2009	



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/550.419 - Conf.# 3350 INFORMATION DISCLOSURE Filing Date September 20, 2005 STATEMENT BY APPLICANT First Named Inventor Thomas Pittelkow Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Sheet 2 of 2 Attorney Docket Number 05432/100M680-US1

/NIQ1	Anzalone and Hirsch, J Org Chem, 1985, (50):2128-2133	
/N.C./22	Forney, J Org Chem, 1971 (36):689-693	
/NI 0 /23	Sugimori and Yashima, Chemistry Letters, 1980, 483-486	
77 24	J Chem Soc, 77; 1900; 278	

*EXAMINER; initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature /Nizal Chandrakumar/	Date Considered	05/15/2009
---	--------------------	------------

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No.

> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

February 9, 2006 Date

Registration Number, if applicable

Telephone Number

Each paper must have its own certificate of mailing, or this certificate must identify Note: each submitted paper.

Information Disclosure Statement (4 pp.) Form PTO/SB/08 (1 p.)

Copies of 19 references (Document Nos. 6-24) Copy of International Search Report (6 pp.)

Return Receipt Postcard